M&A Deal Summary

Quotient Sciences Acquires Arcinova

On February 9, 2021, Quotient Sciences acquired life science company Arcinova from BGF

Acquisition Highlights
  • This is Quotient Sciences’ 5th transaction in the Life Science sector.
  • This is Quotient Sciences’ 3rd transaction in the United Kingdom.

M&A Deal Summary

Date 2021-02-09
Target Arcinova
Sector Life Science
Buyer(s) Quotient Sciences
Sellers(s) BGF
Deal Type Add-on Acquisition
Advisor(s) KPMG Corporate Finance (Financial)
Womble Bond Dickinson (Legal)

Target

Arcinova

Northumberland, United Kingdom
Arcinova is a multiservice contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotechnology companies across the globe in developing their life changing medicines. Arcinova was founded in 2015 and is based in Northumberland, United Kingdom.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Quotient Sciences

Nottingham, United Kingdom

Category Company
Founded 1990
Sector Life Science
DESCRIPTION

Quotient Sciences is a provider of outsourced, early-stage drug development services to the pharmaceutical industry. Quotient Sciences has brought innovation to the pharmaceutical services sector through its unique Translational Pharmaceutics® platform, which is proven to accelerate development timelines, reduce development costs, and drive improvement in R&D productivity. Quotient Sciences was founded in 1990 and is based in Nottingham, England.


DEAL STATS #
Overall 5 of 5
Sector: Life Science M&A 5 of 5
Type: Add-on Acquisition M&A Deals 4 of 4
Country: United Kingdom M&A 3 of 3
Year: 2021 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-11-14 Pharmaterials

Reading, United Kingdom

Pharmaterials Ltd. is a contract development and manufacturing organization. The company’s portfolio of services spans the characterization and optimization of drug substance physical forms, the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply.

Buy -

Seller(S) 1

SELLER

BGF

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 2011
PE ASSETS 2.5B GBP
Size Large
Type Sector Agnostic
DESCRIPTION

Business Growth Fund (BGF) is a private investment firm focused on early and growth-stage investing across the UK. The Firm also invests in publicly traded companies. BGF's growth team looks to invest £1 to £15 million in small to mid-sized companies looking for additional capital to pursue growth. BGF was established in 2011 and is headquartered in London.


DEAL STATS #
Overall 50 of 131
Sector: Life Science M&A 2 of 3
Type: Add-on Acquisition M&A Deals 24 of 70
Country: United Kingdom M&A 47 of 125
Year: 2021 M&A 4 of 25
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-04 Renal Services

London, United Kingdom

Renal Services (UK) Ltd. is a provider of dialysis in the UK. The company currently runs six dialysis centres across the UK, operating 63 dialysis stations and treating approximately 700 permanent and transient patients on behalf of the NHS.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-11 Olive Communications

High Wycombe, United Kingdom

Olive Communications Ltd. is an independent business telecommunications provider, operating from seven regional offices across the UK. The company currently manages nearly 100,000 business customers, delivering communication services and unified solutions across fixed line voice, connectivity and cloud computing. Olive Communications is based in High Wycombe, United Kingdom.

Sell -